Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $778

Benzinga Newsdesk www.benzinga.com Negative 52.6%

Neg 52.6% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $796 to $778.